Clinical trial · Interventional
Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer
NCT00316433CI-TRIAL-00000661terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irinotecan (CPT-11) | Drug | Irinotecan | ALIAS |
| Oxaliplatin (Eloxatin) | Drug | Oxaliplatin | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Previously untreated extensive small cell lung cancer * No prior chemotherapy * No prior radiotherapy except for the treatment of brain metastases Exclusion Criteria: * Prior treatment for extensive stage small cell lung cancer * Known hypersensitivity to any of the components of oxaliplatin or CPT-11 * Greater than grade 2 peripheral neuropathy * Known HIV or Hepatitis B or C (active, previously treated or both)
References
Publications (0)
Data not yet available
No reference posted for this study.